Bär & Karrer Advises Armira and Dr. Urs Spitz on the Sale of Biosynth Carbosynth to KKR

Armira and CEO Dr. Urs Spitz have agreed to sell Biosynth Carbosynth to KKR & Co. Inc. Biosynth Carbosynth is a leading life sciences reagents, custom synthesis and manufacturing services company. CEO Dr. Urs Spitz and senior managers of the group will retain a significant ownership stake in the group. Completion of the transaction is subject to merger control approval.

Bär & Karrer acts as legal advisor to Armira and Dr. Urs Spitz in this transaction. The team is co-led by Christoph Neeracher and Raphael Annasohn and further includes Lukas Bründler, Nicola Schön and Lazar Lepir (all M&A), Susanne Schreiber, Raoul Stocker, Elena Kumashova and Patrick Schmid (all Tax), Markus Wang and Annina Läubli (both IP/IT), Rehana Harasgama (Data Protection), Kilian Müller (Real Estate), Laura Widmer and Fanny Sutter (both Employment), Ralph Malacrida and Tim Salz (both Financing) as well as Mani Reinert and Tobias Rebmann (both Antitrust).